Page last updated: 2024-12-06

tridihexethyl

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mesaconitine: RN given refers to parent cpd(1alpha,3alpha,6alpha,14alpha,15alpha,16beta)-isomer [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

tridihexethyl: synonym Pathilon refers to chloride; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID102004423
SCHEMBL ID17775088
MeSH IDM0046885
PubMed CID20299
CHEMBL ID1201354
CHEBI ID9701
SCHEMBL ID94230
MeSH IDM0046885

Synonyms (38)

Synonym
mesaconitine
2752-64-9
SCHEMBL17775088
AKOS037514735
tridihexethyl cation
tridihexethyl ion
CHEMBL1201354
propethonum
3-cyclohexyl-n,n,n-triethyl-3-hydroxy-3-phenylpropan-1-aminium
CHEBI:9701 ,
BPBIO1_001062
PRESTWICK2_001042
PRESTWICK3_001042
NCGC00179360-01
AB00514015
60-49-1
tridihexethyl
C07861
DB00505
BSPBIO_000964
PRESTWICK0_001042
PRESTWICK1_001042
SPBIO_002902
L001320
(3-cyclohexyl-3-hydroxy-3-phenylpropyl)-triethylazanium
benzenepropanaminium, gamma-cyclohexyl-n,n,n-triethyl-gamma-hydroxy-
7he50a367x ,
unii-7he50a367x
SCHEMBL94230
tridihexethyl [vandf]
benzenepropanaminium, .gamma.-cyclohexyl-n,n,n-triethyl-.gamma.-hydroxy-
tridihexethyl [who-dd]
(3-cyclohexyl-3-hydroxy-3-phenylpropyl)triethylammonium
DTXSID0048553
(3-cyclohexyl-3-hydroxy-3-phenylpropyl)triethylazanium
Q7841414
NCGC00179360-05
benzenepropanaminium,g-cyclohexyl-n,n,n-triethyl-g-hydroxy-

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"Therapeutic applications of Fuzi (lateral root of Aconitum carmichaeli Debx) are seriously concerned with its toxic effects."( Circadian clock regulates metabolism and toxicity of Fuzi(lateral root of Aconitum carmichaeli Debx) in mice.
Dong, D; Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020
)
0.56
" ZT10 dosing of Fuzi generated higher systemic exposures of three toxic alkaloid ingredients aconitine (AC), hypaconitine (HA) and mesaconitine (MA) compared to ZT22."( Circadian clock regulates metabolism and toxicity of Fuzi(lateral root of Aconitum carmichaeli Debx) in mice.
Dong, D; Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020
)
0.56
" However, MA is a highly toxic ingredient."( Study on the Mechanism of Mesaconitine-Induced Hepatotoxicity in Rats Based on Metabonomics and Toxicology Network.
Chen, D; Chen, Q; Jiao, J; Jiao, M; Li, F; Yin, Y; Zhang, J; Zhang, K, 2022
)
0.72

Pharmacokinetics

ExcerptReferenceRelevance
" The validated method was employed to simultaneous quantitation and successfully used for the first time for the pharmacokinetic evaluation of the six Aconitum alkaloids after intravenous drop administration of "SHEN-FU" injectable powder in phase I clinical trial."( Simultaneous quantitation of aconitine, mesaconitine, hypaconitine, benzoylaconine, benzoylmesaconine and benzoylhypaconine in human plasma by liquid chromatography-tandem mass spectrometry and pharmacokinetics evaluation of "SHEN-FU" injectable powder.
Chen, LJ; Duan, JG; Li, R; Tang, MH; Wang, XH; Wei, YQ; Zhang, F; Zhao, X, 2008
)
0.35
" The intestinal absorption and pharmacokinetic characters of 3 diester diterpenoid alkaloids in the precipitation were investigated."( Study on intestinal absorption and pharmacokinetic characterization of diester diterpenoid alkaloids in precipitation derived from fuzi-gancao herb-pair decoction for its potential interaction mechanism investigation.
Fu, CM; He, Y; He, YX; Liao, W; Yan, D; Zhang, JM, 2013
)
0.39
" Moreover, by means of determination of the plasma concentration, the pharmacokinetic characters of 3 alkaloid compounds in rats have been developed."( Study on intestinal absorption and pharmacokinetic characterization of diester diterpenoid alkaloids in precipitation derived from fuzi-gancao herb-pair decoction for its potential interaction mechanism investigation.
Fu, CM; He, Y; He, YX; Liao, W; Yan, D; Zhang, JM, 2013
)
0.39
"05), while T1/2, AUC0-t and Cmax of BAC, BHA increased (P<0."( The effects of Rhizoma Zingiberis on pharmacokinetics of six Aconitum alkaloids in herb couple of Radix Aconiti Lateralis-Rhizoma Zingiberis.
Cai, BC; Cui, XB; Li, JS; Li, W; Peng, WW; Wen, HM; Yang, GM; Zhang, YX, 2013
)
0.39
" Compared with single-herb extracts, alkaloids in plasma (except methylephedrine, benzoylmesaconine and benzoylhypaconine) showed slower elimination (the mean residence time or half-life was longer), although the maximum plasma concentration and area under the plasma concentration curve values decreased."( Simultaneous quantification and pharmacokinetics of alkaloids in Herba Ephedrae-Radix Aconiti Lateralis extracts.
Huo, H; Li, H; Luo, J; Song, S; Tang, Q; Xing, X,
)
0.13
"To investigate therapeutic effects and pharmacokinetic profiles of aconitine-type alkaloids in CHF rats."( Pharmacokinetics of aconitine-type alkaloids after oral administration of Fuzi (Aconiti Lateralis Radix Praeparata) in rats with chronic heart failure by microdialysis and ultra-high performance liquid chromatography-tandem mass spectrometry.
Cao, Y; Xiong, YK; Yu, B, 2015
)
0.42
" Pharmacokinetic analyses showed that the area under the curve (AUC) values (reflective of systemic exposure) and renal distribution of aconitine, hypaconitine and mesaconitine (three putative active constituents) for Fuzi dosing at ZT10 were significantly higher than those for herb dosing at ZT22, suggesting a role of circadian pharmacokinetics in Fuzi chronoefficacy."( Pharmacokinetics-based chronoefficacy of Fuzi against chronic kidney disease.
Gao, L; Lin, J; Lin, Y; Su, C; Wang, S; Wang, Z; Wu, B; Yang, Z, 2021
)
0.62

Bioavailability

ExcerptReferenceRelevance
" These observations indicated that the three alkaloids may not only be P-gp inhibitors but also its substrates; they interact with each other and can potentially enhance their own bioavailability when taken concomitantly."( Intestinal transport of pure diester-type alkaloids from an aconite extract across the Caco-2 cell monolayer model.
Li, N; Liu, Z; Ma, J; Sui, Z; Tsao, R, 2012
)
0.38
" For in-vitro experiment, the modified Franz diffusion cell method was used to determine the transdermal absorption rate and 24h cumulative transdermal absorption amount of the active ingredients of crossbow-medicine liquid."( Effect of microneedle roller on promoting transdermal absorption of crossbow-medicine liquid via transdermal administration of Traditional Chinese Medicine and the safety of crossbow-medicine needle therapy: An experimental study.
Cui, J; Luo, H; Zan, F, 2023
)
0.91
" The 24h cumulative transdermal absorption amount and transdermal absorption rate of each ingredient in microneedle-roller group were significantly higher than those in crossbow-medicine liquid application group (all P < 0."( Effect of microneedle roller on promoting transdermal absorption of crossbow-medicine liquid via transdermal administration of Traditional Chinese Medicine and the safety of crossbow-medicine needle therapy: An experimental study.
Cui, J; Luo, H; Zan, F, 2023
)
0.91

Dosage Studied

ExcerptRelevanceReference
"Toxicity was determined based on assessment of heart injury and animal survival after dosing mice with Fuzi decoction at different circadian time points."( Circadian clock regulates metabolism and toxicity of Fuzi(lateral root of Aconitum carmichaeli Debx) in mice.
Dong, D; Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020
)
0.56
" ZT10 dosing of Fuzi generated higher systemic exposures of three toxic alkaloid ingredients aconitine (AC), hypaconitine (HA) and mesaconitine (MA) compared to ZT22."( Circadian clock regulates metabolism and toxicity of Fuzi(lateral root of Aconitum carmichaeli Debx) in mice.
Dong, D; Gao, L; Lin, Y; Wang, S; Wu, B; Yang, Z; Zhou, Z, 2020
)
0.56
" In this study, we uncovered that the therapeutic effect of Fuzi (the lateral root of Aconitum carmichaelii Debeaux) depended on the dosing time in mice with adenine-induced chronic kidney disease (CKD)."( Pharmacokinetics-based chronoefficacy of Fuzi against chronic kidney disease.
Gao, L; Lin, J; Lin, Y; Su, C; Wang, S; Wang, Z; Wu, B; Yang, Z, 2021
)
0.62
"The Fuzi efficacy was higher when the drug was dosed at ZT10 and was lower when the drug was dosed at other times (ZT2, ZT6, ZT14, ZT18 and ZT22) according to measurements of plasma CRE, BUN and urinary NAG."( Pharmacokinetics-based chronoefficacy of Fuzi against chronic kidney disease.
Gao, L; Lin, J; Lin, Y; Su, C; Wang, S; Wang, Z; Wu, B; Yang, Z, 2021
)
0.62
"The efficacy of Fuzi against CKD depends on the dosing time in mice, which is associated with circadian pharmacokinetics of the three main active constituents (i."( Pharmacokinetics-based chronoefficacy of Fuzi against chronic kidney disease.
Gao, L; Lin, J; Lin, Y; Su, C; Wang, S; Wang, Z; Wu, B; Yang, Z, 2021
)
0.62
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
anti-ulcer drugOne of various classes of drugs with different action mechanisms used to treat or ameliorate peptic ulcer or irritation of the gastrointestinal tract.
muscarinic antagonistA drug that binds to but does not activate muscarinic cholinergic receptors, thereby blocking the actions of endogenous acetylcholine or exogenous agonists.
antispasmodic drugA drug that suppresses spasms. These are usually caused by smooth muscle contraction, especially in tubular organs. The effect is to prevent spasms of the stomach, intestine or urinary bladder.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
tertiary alcoholA tertiary alcohol is a compound in which a hydroxy group, -OH, is attached to a saturated carbon atom which has three other carbon atoms attached to it.
quaternary ammonium ionA derivative of ammonium, NH4(+), in which all four of the hydrogens bonded to nitrogen have been replaced with univalent (usually organyl) groups.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency39.81070.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (1)

Assay IDTitleYearJournalArticle
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (104)

TimeframeStudies, This Drug (%)All Drugs %
pre-199021 (20.19)18.7374
1990's16 (15.38)18.2507
2000's21 (20.19)29.6817
2010's34 (32.69)24.3611
2020's12 (11.54)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 29.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index29.95 (24.57)
Research Supply Index2.64 (2.92)
Research Growth Index4.13 (4.65)
Search Engine Demand Index32.00 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (29.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Trials2 (18.18%)5.53%
Reviews3 (3.03%)6.00%
Reviews0 (0.00%)6.00%
Case Studies3 (3.03%)4.05%
Case Studies1 (9.09%)4.05%
Observational0 (0.00%)0.25%
Observational0 (0.00%)0.25%
Other93 (93.94%)84.16%
Other8 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]